AXT, Inc. moved to expand its financing headroom and scale up production for AI-related components, proposing at its May 14, 2026 annual meeting to raise its authorized common shares from 70 million to 120 million and announcing plans to double manufacturing capacity for indium phosphide — a material in growing demand for AI data-center infrastructure. The combination of a larger share authorization and the capacity push sent AXT’s stock sharply lower, falling about 12.8% on the news.
Company materials tied the share-cap increase directly to the indium phosphide expansion, signaling management’s intent to align AXT’s capital structure with what it describes as accelerating AI-driven demand. Indium phosphide is a substrate used in high-frequency photonics and optoelectronics that power data-center interconnects and other AI hardware; AXT said it expects robust demand as cloud providers and hyperscalers continue to build out AI infrastructure. The move to double production capacity is presented as the operational response to that opportunity.
AXT’s recent financials show the gap between opportunity and current performance. For fiscal 2025 the firm reported revenue of US$88.33 million and a net loss of US$21.26 million, even as management highlighted a backlog exceeding US$60 million. The company’s own projections outline a return to profitability and growth, forecasting revenue of about US$117.8 million and earnings of US$16.6 million by 2028 — a trajectory that requires sustained revenue growth and margin improvement from current levels.
Market observers and analysts remain divided on how quickly AXT can translate backlog into shipped product and positive earnings. The most bullish analyst scenarios referenced by the company envision much larger outcomes — roughly US$318 million in revenue and nearly US$120 million in earnings by 2029 — but those upside paths assume aggressive capacity execution and the easing of regulatory frictions that have weighed on margins and shipments. AXT itself has warned that export permit constraints and margin pressures remain material near-term risks to that narrative.
Raising the authorized share count does not by itself dilute existing holders, but it gives the board flexibility to issue new equity should it choose to fund the expansion through share sales rather than, or in combination with, debt or internal cash flow. Investors reacted negatively to the prospect of potential dilution and to uncertainty over the financing mix needed to complete the InP capacity build-out, contributing to the stock’s steep intraday decline after the announcements.
The coming months will focus on execution details: how AXT plans to finance the capex required for the capacity increase, the timeline for bringing additional indium phosphide lines online, and whether export and permitting hurdles can be managed without further squeezing margins. For now, the company is staking its short- to medium-term strategy on converting AI-related demand into higher-volume, profitable shipments — a bet that markets are treating as promising but risky until results show otherwise.